Africa is building community‑centric biotech hubs that focus on localising production of essential medicines, vaccines, and diagnostics. Kigali’s biotech cluster is a leading example, combining R&D labs, manufacturing units, and training centres in one ecosystem.
Localised production reduces dependence on imports and strengthens outbreak readiness. Start‑ups in Rwanda are developing low‑cost diagnostic kits tailored for malaria, meningitis, and viral infections.
Scaling remains difficult due to financing gaps and the need for specialised scientific talent. Still, regional biotech hubs are poised to become crucial pillars of Africa’s long‑term public‑health security.
